A Smart Theranostic Prodrug System Activated by Reactive Oxygen Species for Regional Chemotherapy of Metastatic Cancer

Angew Chem Int Ed Engl. 2022 Mar 14;61(12):e202116807. doi: 10.1002/anie.202116807. Epub 2022 Feb 3.

Abstract

Metastatic cancer is difficult to cure because of its uncontrollable nature and side effects during treatment. We constructed a reactive oxygen species (ROS)-activated smart theranostic prodrug system based on an ROS active site linked with both a targeting group and an anticancer drug for efficient regional chemotherapy of metastatic cancers. The optimized prodrug (Bio-(8)-MB-CPT) with biotin as the targeting group displayed high sensitivity towards ROS and selectively targeting ability towards cervical cancer cells, showing highly efficient drug release (up to 92 %) in vitro. Bio-(8)-MB-CPT thus exerted strong toxicity towards cervical cancer cells, but unlike the parent drug (camptothecin), showed no toxicity towards normal cells. Moreover, the prodrug displayed significantly enhanced antitumor efficacy in vivo and eradicated the tumor with no obvious side effects (inhibition of the tumor reached up to 99.9 %).

Keywords: Metastatic Cancer; Prodrug; Reactive Oxygen Species; Regional Chemotherapy; Theranostic Agent.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Camptothecin / pharmacology
  • Camptothecin / therapeutic use
  • Cell Line, Tumor
  • Drug Liberation
  • Female
  • Humans
  • Nanoparticles* / chemistry
  • Prodrugs* / chemistry
  • Prodrugs* / pharmacology
  • Prodrugs* / therapeutic use
  • Reactive Oxygen Species
  • Theranostic Nanomedicine
  • Uterine Cervical Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Prodrugs
  • Reactive Oxygen Species
  • Camptothecin